Compumedics Posts Record $60.3M FY26 Revenue with SaaS Growth Surging 70%

Record Revenue and SaaS Expansion Drive FY26 Growth

Compumedics Limited (ASX:CMP) closed FY26 with record shipped and invoiced revenue of approximately $60.3 million, marking an 18% increase over the prior year. This milestone was underpinned by strong performances across its sleep diagnostics, neurology, MEG, and connected platform businesses. Notably, the company’s Somfit and Nexus 360 SaaS recurring revenues surged by around 70%, highlighting the growing importance of subscription-based income streams despite Somfit D's commercial release in the US still pending.

MEG Progress and Supply Chain Resolution

The magnetoencephalography (MEG) segment, a high-value growth platform for Compumedics, experienced shipment delays during FY26 due to helium supply disruptions linked to geopolitical tensions in the Middle East. These issues have now been resolved, allowing existing MEG orders to progress through manufacture, shipment, and installation. Recent invoicing for MEG systems was completed in June, although FY26 revenue recognition fell short of the company’s April guidance range of $62 million to $65 million, primarily due to these timing factors rather than a drop in demand.

Somfit D Manufacturing and US Market Strategy

Compumedics continues its deliberate, quality-focused approach toward the US launch of Somfit D, its home sleep testing device. Manufacturing commitments are now in place, with the company working through remaining steps for commercial release. The cautious rollout strategy reflects the company’s intent to ensure reliability and market readiness before full-scale deployment. The US home sleep testing market represents a significant opportunity, and Compumedics remains optimistic about Somfit D’s long-term potential.

Board Changes and Leadership Update

Amid these operational developments, Non-Executive Director Christopher R. Barys resigned effective 30 June 2026 by mutual agreement as the company enters its next growth phase. Barys had been appointed in September 2025, bringing valuable US MedTech and capital markets experience to Compumedics. Executive Chairman David Burton acknowledged Barys’ contributions to the US growth strategy and investor engagement during his nine-month tenure.

Outlook for FY27: Accelerated Growth and EBITDA Expansion

Looking ahead, Compumedics aims for further double-digit revenue growth in FY27, supported by a strong order book of approximately $62.7 million and a healthy sales pipeline. The company expects EBITDA to grow at a faster rate than revenue, driven by cost discipline and increased contributions from higher-quality recurring revenue platforms. Key catalysts include ongoing MEG order fulfillment, expansion of connected SaaS platforms, and the anticipated US commercial release of Somfit D. The board and management maintain confidence in the medium-term growth trajectory, leveraging Compumedics’ differentiated technology and global footprint.